What did @dailymail actually say?
A creator identifying as a singer named Avery claimed she developed osteoporosis and osteopenia after taking Ozempic for approximately one year for weight loss. Fresh from a doctor's visit, she said she has "significant bone loss" and attributed it directly to Ozempic, concluding that "that's what happens if you" use "Ozempic for weight loss and you lose too much weight." She also mentioned a history of struggling with an eating disorder before starting the medication.
The video has 17.3 million views. That reach matters, because the claim lands somewhere between plausible and dangerously oversimplified, and most viewers won't have the context to tell the difference.
Does the science back this up?
Partly, yes. GLP-1 receptor agonists like semaglutide are genuinely associated with reduced bone mineral density, but the picture is more complicated than one year of Ozempic causing osteoporosis in an otherwise healthy 30-year-old.
A 2023 meta-analysis by Dong et al. in Diabetes, Obesity and Metabolism found that GLP-1 receptor agonists were associated with modest reductions in bone mineral density at the hip and lumbar spine, though fracture risk data remain mixed. Critically, the bone loss seen in GLP-1 trials is largely explained by rapid weight loss itself, not necessarily a direct drug effect on bone metabolism. When you lose weight quickly, you lose mechanical loading on the skeleton. Less load, less bone.
A separate concern is muscle mass. The SURMOUNT and STEP trials both documented lean mass loss alongside fat loss on GLP-1 therapies. Muscle drives bone remodeling. Lose the muscle, and bone density follows. This mechanism is well-established and predates GLP-1 drugs entirely.
What makes this creator's case harder to evaluate is her disclosed history of an eating disorder. Malnutrition and low body weight are among the strongest independent risk factors for osteoporosis at any age. A 2021 review by Misra and Klibanski in Bone documented severe bone deficits in young women with anorexia nervosa, often irreversible. Without knowing her baseline bone density before Ozempic, attributing her current diagnosis entirely to the drug is a significant leap.
What did they get wrong (or right)?
She got the general mechanism right: rapid weight loss on GLP-1 drugs can reduce bone density. That part holds up. The error is in how she frames causation. Saying "that's what happens if you" take Ozempic for weight loss flattens a genuinely complex situation into a single-drug accusation.
Her eating disorder history is not a footnote. It is potentially the dominant factor in her bone health. The American Society for Bone and Mineral Research has flagged that patients with prior restrictive eating disorders who then lose significant additional weight on GLP-1 drugs face compounded skeletal risk. That compounded risk is real, but it is not the same as saying Ozempic alone caused her osteoporosis in 12 months.
She also doesn't mention calcium intake, vitamin D status, physical activity, or whether she was resistance training, all variables that would significantly affect the outcome. A 30-year-old developing frank osteoporosis in one year of drug use, absent a prior eating disorder, would be extraordinary and would warrant a case report in a medical journal, not just a TikTok. With the eating disorder context, it becomes much less surprising and much less attributable to the drug alone.
What should you actually know?
If you are taking or considering a GLP-1 medication, bone health is a legitimate concern worth discussing with your provider, especially if you have any history of disordered eating, low body weight, or are losing weight rapidly. This is not a reason to avoid GLP-1 therapy if it is medically appropriate for you. It is a reason to be monitored properly.
Current clinical guidance from the Endocrine Society recommends that patients on GLP-1 therapies who are losing significant weight should prioritize resistance exercise, adequate protein intake, and sufficient calcium and vitamin D. A baseline DEXA scan is reasonable for high-risk patients. These are conversations to have with a doctor before and during treatment, not after a TikTok video.
The real problem this video exposes is not that Ozempic is secretly destroying bones. It is that 17 million people watched a single individual's medical case without the context of her eating disorder history, her baseline bone density, her nutritional status, or any of the factors that would let you generalize or not generalize from her experience.
Her experience deserves to be taken seriously. The causal story she tells about it does not deserve to be taken at face value.